Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Multiple Sclerosis, Relapsing-Remitting Participants with RR-MS, according to the revised McDonald (2010) Participants with an expanded disability status scale (EDSS) score between 0 and 3 before screening visit and before relapse Participants receiving treatment with IFN beta 1a 44 mcg three times a week for at least 6 months but for no more than 10 years before the screening visit Female participants must be neither pregnant nor breastfeeding and must lack childbearing potential Participants willing and able to comply with the protocol for the total duration of the study Participants able to understand the purposes and the risks of the study Participants have signed the appropriate written informed consent form, approved by the Independent Ethics Committee (IEC), prior to the performance of any study activities For MS participants with relapse Deterioration of at least one step in a relevant Functional Systems Scale (FSS) or an increase in EDSS of 1 point or more compatible, according to physician's judgment, with the therapy prosecution Relapse started within maximum 5 days before the in the study  Participants with diagnosis of primary progressive MS (PP-MS) Participants have any disease other than MS that could better explain his/her signs and symptoms Participants with any comorbidity with diseases that might alter synaptic plasticity (example Parkinson Disease, Alzheimer Disease, Stroke) Participants receiving concomitant treatment with drugs that may alter synaptic plasticity (example, cannabinoids) Participants with history or presence of any unstable medical condition (tumor or chronic infection or severe life threatening infection within the last 6 months) Participants who have received any corticosteroids therapy within 3 months prior to the screening Participants with any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressive agents during the course of the study Participants who have received any immunosuppressive agents other to corticosteroids, as monotherapy or combination therapy within 3 months prior to the screening visit Participants with history or currently active primary or secondary immunodeficiency Participants with inadequate liver function, defined by alanine aminotransferase (ALT) > 3 * upper limit of normal (ULN), or alkaline phosphatase (AP) > 2 * ULN, or total bilirubin > 2 * ULN if associated with any elevation of ALT or AP